Tubulis
Key Facts
| Invested since | 2020 |
| Based in | Munich |
About the company
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication.
Do you want to
know more about this company?
Tubulis in the news
zum Artikel
“Creating a new option for hard-to-treat cancers”– Interview with Dominik Schumacher, CEO and co-founder of Tubulis
zum Artikel
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
zum Artikel
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
zum Artikel
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
More startups from Life Sciences
VACIS is the leading tissue engineering company for body-own blood vessels. The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing …
to Vacis
Refined Laser Systems GmbH, based in Münster, Germany, was founded in 2019 as a spin-off from University of Münster by Max Brinkmann, Tim Hellwig and Christoph Seidenstücker. The company’s core …
to Refined Laser Systems
CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in …
to CustomSurg
neotiv is a spin-off of the Otto von Guericke University in the German city of Magdeburg in close collaboration with the Magdeburg site of the German Centre for Neurodegenerative Diseases …
to neotiv
Altavo is a Dresden based medical technology startup founded in February 2021. Based on non-invasive radar sensing and AI algorithms for speech recognition and synthesis, Altavo is developing prosthetics to …
to Altavo
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
to faCellitate
Exit
Sonormed is focused on digital medical products and builds the appropriate audiological infrastructure to adress the potential that large numbers of unserviced hearing damages, among them tinnitus, provide worldwide and …
to Sonormed
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …
to Refoxy Pharma
Hapila’s counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.
to HAPILA
Exit
First-in-class Entry-Inhibitor for the treatment of chronic hepatitis Delta
to MYR
ADVANOVA was founded in January 2012 by Dr. Frank Hemer, a doctor and computer scientist, and Bastian Bleisinger, a computer scientist. The company’s head office is in Erlangen at the …
to Advanova
MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®. Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases …
to MDTB Cell Manufacturing